Our top pick for
Building a portfolio
Lipocine Inc is a biotechnology business based in the US. Lipocine shares (LPCN) are listed on the NASDAQ and all prices are listed in US Dollars. Lipocine employs 12 staff and has a market cap (total outstanding shares value) of USD$108.4 million.
|Latest market close||USD$1.32|
|52-week range||USD$0.301 - USD$2.39|
|50-day moving average||USD$1.4185|
|200-day moving average||USD$1.3956|
|Wall St. target price||USD$3|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.551|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-12)||N/A|
|1 month (2020-12-23)||-6.38%|
|3 months (2020-10-19)||N/A|
|6 months (2020-07-19)||N/A|
|1 year (2020-01-19)||N/A|
|2 years (2019-01-19)||N/A|
|3 years (2018-01-19)||N/A|
|5 years (2016-01-19)||N/A|
|Gross profit TTM||USD$-5,053,695|
|Return on assets TTM||-49.42%|
|Return on equity TTM||-179.39%|
|Market capitalisation||USD$108.4 million|
TTM: trailing 12 months
There are currently 4.0 million Lipocine shares held short by investors – that's known as Lipocine's "short interest". This figure is 0.8% down from 4.0 million last month.
There are a few different ways that this level of interest in shorting Lipocine shares can be evaluated.
Lipocine's "short interest ratio" (SIR) is the quantity of Lipocine shares currently shorted divided by the average quantity of Lipocine shares traded daily (recently around 918123.90804598). Lipocine's SIR currently stands at 4.35. In other words for every 100,000 Lipocine shares traded daily on the market, roughly 4350 shares are currently held short.
However Lipocine's short interest can also be evaluated against the total number of Lipocine shares, or, against the total number of tradable Lipocine shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lipocine's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Lipocine shares in existence, roughly 60 shares are currently held short) or 0.0623% of the tradable shares (for every 100,000 tradable Lipocine shares, roughly 62 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lipocine.
Find out more about how you can short Lipocine stock.
We're not expecting Lipocine to pay a dividend over the next 12 months.
Lipocine's shares were split on a 1:100 basis on 25 July 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lipocine shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Lipocine shares which in turn could have impacted Lipocine's share price.
Over the last 12 months, Lipocine's shares have ranged in value from as little as $0.301 up to $2.39. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lipocine's is 0.8016. This would suggest that Lipocine's shares are less volatile than average (for this exchange).
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that completed Phase 2b testing; LPCN 1148, an oral prodrug of bioidentical testosterone for the treatment of non-alcoholic steatohepatitis cirrhosis (NASH); LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth; and LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase 2 Clinical trial for the treatment of NASH. Lipocine Inc. is headquartered in Salt Lake City, Utah.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.